B-Cell Lymphoma ML43389Study #ML43389
An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies.
B-Cell Lymphoma ML43389 will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin’s lymphoma [NHL]).
Sponsor: Genentech, Inc.
Principal Investigator: Dr. Tara GraffBack To Clinical Trials NCI Database Entry